Foley Partner David Rosen was quoted in an article that appeared in Genetic Engineering & Biotechnology News on October 12, 2011 titled “Extent of Feedback on RUO/IUO In Vitro Dx Draft Guidance Means Changes Not Expected Soon.” Rosen discusses draft guidance proposed by the FDA concerning the labeling of in vitro diagnostic (IVD) products marked “for research use only” (RUO) and “for investigational use only” (IUO). He states that some companies are concerned about what products they can sell as RUO/IUO tests and what they cannot under the FDA’s draft guidelines. Rosen recognizes the need for research, but notes that it is also important to ensure that people do not rely on tests that are not verified and validated.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”